Peptone is a biotechnology company developing small-molecule therapeutics that selectively target intrinsically disordered proteins (IDPs) using bespoke mass spectrometry and next-generation machine learning. This approach addresses the challenge of drugging disease-related proteins that are difficult to target due to their structural variability.
Funding
$40.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-related proteins are intrinsically disordered proteins (IDPs), which lack a stable 3D structure, making them difficult to target with traditional drug discovery methods. These proteins play a role in various diseases, but their structural variability poses a significant challenge for developing effective therapeutics.
Solution
Peptone is a biotechnology company that develops small-molecule therapeutics targeting intrinsically disordered proteins (IDPs). The company employs a technology platform that combines bespoke mass spectrometry and next-generation machine learning to model IDPs of any size or complexity. This approach enables the identification of druggable pockets on these proteins, which are otherwise difficult to detect. Peptone's technology provides insights into protein structure and function, facilitating the design of small molecules that selectively bind to and modulate IDP activity.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for diseases involving intrinsically disordered proteins.
Features
- Proprietary mass spectrometry techniques for characterizing the dynamic structures of IDPs
- GPU-accelerated data analysis for modeling IDP conformations and identifying potential binding sites
- Machine learning algorithms for predicting small-molecule interactions with IDPs
- Generative AI for designing small molecules that selectively target IDPs
- Assay development and efficacy testing to validate therapeutic candidates